We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Inkjet-Printed Diagnostics-on-Demand Demonstrated at AACC 2015

By LabMedica International staff writers
Posted on 17 Aug 2015
An inkjet-based innovation for high-tech printing on paper opens the door to lower cost, rapid (point-of-care) POC testing, and was demonstrated during the 2015 AACC Meeting & Clinical Lab Expo (July 26-30; Atlanta, GA, USA).

The new XylemDx technology developed Cambridge Consultants (Cambridge, UK) is set to bring a breakthrough innovation to POC diagnostics. More...
Ingenious use of inkjet printing techniques has made it possible to create a test cartridge from a single sheet of paper, paving the way for sophisticated low-cost tests that can be adapted at the touch of a button. Also, the digital fabrication technique (once regulatory approval is secured) will give the flexibility to print tests in quantities from one to millions.

Aging populations, the drive for healthcare efficiency, and the rapid rise of “consumer healthcare”—where people manage their own health and well-being—are fueling an increase in POC diagnostics. But the high cost of POC tests compared with centralized lab tests is a challenge. XylemDx enables simple, low-cost, near-instant personalized testing, for example, at the pharmacy or doctor’s surgery, for signs ranging from the latest strain of the flu virus to biomarkers for genetic conditions. In developing countries, it could play a crucial role in mobile-clinic diagnostics and in pandemic monitoring and screening of large populations during an outbreak of Ebola, for example.

XylemDx turns a sheet of paper into any one of a variety of different tests, each of which can be produced on the same fabrication device. Each test paper can be configured with a custom set of test modules (such as electronic, thermal, fluidic, optical, or biological reagent modules) before being folded concertina-style into the traditional test cartridge shape. For diagnostic manufacturers, this opens up the possibility of low-cost prototyping and development, as well as a universal production methodology. The modules “toolbox” enables customization for a particular patient or specific strain of disease.

The test modules are printed with inkjet-based printing techniques that use wax to lay down fluidic pathways, electronic ink containing silver nanoparticles to allow electrical connectivity, and so on. The paper cartridges can be configured for various samples types (such as blood, urine, saliva, or mucus) and various readers (from complex diagnostic instruments to a reader on the back of a smartphone or a simple USB-powered device).

“Diagnostic tests underpin crucial healthcare decisions so it’s vital they are as fast, accurate, flexible, and cost-effective as possible,” said John Pritchard, head of diagnostics at Cambridge Consultants, “Cambridge Consultants has a rich history of inkjet printing and we’ve now brought that expertise to the world of POC diagnostics. Combined with our extensive scientific and engineering knowledge—including our long track record in the low-cost, high-performance optics that many of these tests require—it’s resulted in a radical new way of providing diagnostics on demand.”

Related Links:

Cambridge Consultants



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study validated a genetic scoring tool designed to help physicians diagnose idiopathic pulmonary fibrosis and stratify risk for severe outcomes, including death or lung transplantation (Image Credit: Adobe Stock)

Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.